Topotecan in Second-Line Treatment of Small-Cell Lung Cancer - How it Works in Our Daily Clinical Practice?

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|5|2|114-117

ISSN： 1574-8863

Source： Current Drug Safety, Vol.5, Iss.2, 2010-04, pp. : 114-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Topotecan in the First-Line Treatment of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 7-8

Karger

Access to resources Recommend Favorite

Status of Topotecan in Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 1-1

Karger

Access to resources Recommend Favorite

Topotecan (Hycamtin®) in the Therapy of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 31, Iss. 4, 2008-03 ,pp. : 185-189

Karger

Access to resources Recommend Favorite